Evotec, Chinook Collaborate To Discover & Develop Medicines For Chronic Kidney Diseases

Evotec SE (EVTCY.PK,EVOTF.PK) and Chinook Therapeutics Inc. (KDNY) said that they have collaborated to focus on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases or "CKD".

Evotec noted that the collaboration leverages its proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec's unique integrated data analysis platform.

In addition, Chinook will contribute drug discovery and development programs to the collaboration targeting rare kidney diseases such as IgA nephropathy and glomerular diseases.

As per the terms of the deal, Chinook and Evotec will share drug discovery and pre-clinical development responsibilities. Chinook will be responsible for clinical development and commercialization of product candidates developed under the collaboration.

Evotec will receive an undisclosed upfront payment, research funding, and will be eligible to receive progress-dependent milestone payments and tiered royalties on net sales for targets identified through the collaboration.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT